Taken together, peptide therapy promotes a broad immune-activating environment, promoting the accumulation of CD8+ T cells, NK cells, and DCs within tumors, activating DCs within draining LNs, increasing MHC I expression by tumor cells, and upregulating cytotoxic molecules by cells associated with tumor control. The gene discussed is CD8A; the disease is neoplasm.